Risk factor
Very high price volatility
Profitability factor
Very favourable analyst view
About
BrainAurora Medical Technology Limited develops medical-grade digital therapy (DTx) products for cognitive impairment. The company offers the evaluation and intervention of cognitive impairments to treat vascular diseases, neurodegenerative diseases, psychological disorders, and child development deficiencies. It develops the Brain Function Information Management Platform software system, an evidence-based, medical-grade DTx product; Cognitive Ability Testing software; the Cognitive Ability Supplemental Screening and Assessment software; and the Dyslexia Supplemental Screening and Assessment software. The company was founded in 2012 and is based in Shaoxing, China.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of 6681.HK is 7.6 and suggests 83% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell